Scinai Immunotherapeutics (SCNI) Stock Overview
A biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SCNI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Scinai Immunotherapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$6.18 |
| 52 Week Low | US$0.55 |
| Beta | 1.99 |
| 1 Month Change | -21.79% |
| 3 Month Change | -26.20% |
| 1 Year Change | -77.07% |
| 3 Year Change | -96.57% |
| 5 Year Change | -99.83% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate
Dec 15
Why Scinai Immunotherapeutics' (NASDAQ:SCNI) Healthy Earnings Aren’t As Good As They Seem
Nov 29Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31Shareholder Returns
| SCNI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.9% | 3.6% | 4.4% |
| 1Y | -77.1% | 41.4% | 31.9% |
Return vs Industry: SCNI underperformed the US Biotechs industry which returned 40.3% over the past year.
Return vs Market: SCNI underperformed the US Market which returned 31% over the past year.
Price Volatility
| SCNI volatility | |
|---|---|
| SCNI Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: SCNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCNI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 31 | Amir Reichman | www.scinai.com |
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies.
Scinai Immunotherapeutics Ltd. Fundamentals Summary
| SCNI fundamental statistics | |
|---|---|
| Market cap | US$2.08m |
| Earnings (TTM) | -US$8.31m |
| Revenue (TTM) | US$1.31m |
Is SCNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCNI income statement (TTM) | |
|---|---|
| Revenue | US$1.31m |
| Cost of Revenue | US$3.96m |
| Gross Profit | -US$2.65m |
| Other Expenses | US$5.66m |
| Earnings | -US$8.31m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | -202.29% |
| Net Profit Margin | -633.64% |
| Debt/Equity Ratio | 3.6% |
How did SCNI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/06 14:30 |
| End of Day Share Price | 2026/04/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scinai Immunotherapeutics Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| David Bautz | Zacks Small-Cap Research |